Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.

@article{Manegold2005SecondlineC,
  title={Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.},
  author={Christian Manegold and James Thomas Symanowski and Ulrich Gatzemeier and Martin Reck and Joachim von Pawel and Cornelius Kortsik and K. Nackaerts and Pilar Lianes and Nicholas John Vogelzang},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2005},
  volume={16 6},
  pages={923-7}
}
BACKGROUND A phase III trial in patients with malignant pleural mesothelioma demonstrated a survival advantage for pemetrexed plus cisplatin compared with single-agent cisplatin. Because post-study chemotherapy (PSC) may have influenced the outcome of the trial, we examined its use and association with survival. PATIENTS AND METHODS Eighty-four patients from the pemetrexed plus cisplatin arm and 105 patients from the single-agent cisplatin arm received PSC. Kaplan-Meier survival estimates… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Correlation of pulmonary function tests with best tumor response status : Results from the phase III study of pemetrexed + cisplatin vs . cisplatin in malignant pleural mesothelioma

  • P Paoletti, M Pistolesi, JJ Rusthoven
  • Proc Am Soc Clin Oncol
  • 2003

Improving quality of life in patients with malignant pleural mesothelioma : Results of the randomized pemetrexed + cisplatin vs . cisplatin trial using the LCSS - meso instrument

  • RJ Gralla, PJ Hollen, AM Liepa
  • Proc Am Soc Clin Oncol
  • 2003

Similar Papers

Loading similar papers…